By Dietrich Knauth

NEW YORK, June 30 (Reuters) - A Missouri state court on Tuesday set an August 19 hearing date to review Bayer's $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, briefly delaying a hearing that had been set for early July.

Judge Timothy Boyer in St. Louis previously indicated that he would postpone the settlement approval hearing after a dispute over whether the deal should be reviewed in federal court or Missouri state court. While Boyer was considering the schedule, the U.S. Supreme Court last week handed Bayer BAYGn.DE a major legal victory, issuing a ruling that scaled back thousands of claims that Roundup's warning label failed to properly warn consumers about the cancer risk associated with the weedkiller.

The Supreme Court on Tuesday remanded several other Roundup-related cases to lower courts to reconsider in light of its ruling on failure-to-warn claims. Those cases include allegations that were not addressed in the court's recent ruling, including claims that Roundup was defectively designed.

Bayer's Monsanto unit said in a statement Tuesday that the six-week ​delay in state court would not materially impact the settlement approval process. Bayer has previously said the settlement is supported by most of the people who had sued over Roundup claims.

The German drugmaking and crop science company is facing approximately 65,000 claims in U.S. state and federal courts from plaintiffs who say they developed non-Hodgkin lymphoma and ​other forms of cancer after using Roundup at home or on the job. Bayer, which acquired Roundup when it purchased Monsanto in 2018, has said that decades of studies have shown Roundup's key ingredient glyphosate is safe, and does not cause cancer.

The settlement proposal, announced in February, aims to resolve most ⁠of the remaining lawsuits as well as potential lawsuits from people who already have been exposed to Roundup and develop cancer in the future. Dozens of people have objected to the settlement, saying that the deal is unfair ​to cancer victims and future claimants.

The Supreme Court's recent ruling does not change the terms of the settlement, and Bayer has said it remains committed to moving forward with the deal it reached in February.

Bayer's Monsanto unit has said that the Supreme Court ruling significantly strengthens the company's position in Roundup lawsuits brought by plaintiffs who opted out of the settlement.

Failure-to-warn claims were part of most Roundup lawsuits ​and are generally considered easier to prove than other legal theories.

Plaintiffs' lawyers argue that they can still win cases based on other legal theories that were not addressed by the court.

The high court's ruling brought one trial to an abrupt end on Friday, when a different Missouri state court judge declared a mistrial because the case included arguments and evidence tied to failure-to-warn claims that the Supreme Court had ruled were preempted.

The proposed settlement does not resolve about 4,000 Roundup cases that are consolidated in federal court. The judge overseeing those cases, who has previously criticized the proposed settlement, scheduled a July 7 status conference to discuss the impact of the Supreme Court ruling on the pending federal court cases.

The case is King v. Monsanto, City of St. Louis Circuit Court, No. 2622-CC00325

For ​the objecting plaintiffs: Ashley Keller of Keller Postman LLC and R. Prescott Sifton of Frazer PLC

For Bayer: Elaine Golin, Jeffrey Wintner ​and Carrie Reilly of Wachtell Lipton Rosen & Katz; Daniel Nelson and Derek Kraft of Gibson Dunn & Crutcher LLP; James Bennet of Dowd Bennett

Class counsel: Seeger Weiss; Motley Rice; Williams Hart & Boundas; Waters Kraus Paul & Siegel; The Holland Law Firm; Ketchmark & McCreight.

Read more:

What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?

US Supreme Court scales back Roundup cancer suits in win for Bayer

Bayer proposes $7.25 billion plan to settle Roundup cancer cases